ETO Residual Testing for Medical Devices — ISO 10993-7:2023
EO sterilisation is used for over 50% of medical devices globally — but residual EO is a known mutagen and carcinogen, and ethylene chlorohydrin (ECH) and ethylene glycol (EG) by-products are equally controlled. Auriga Research provides NABL-accredited ethylene oxide (ETO) residual testing per ISO 10993-7:2023, quantifying EO, ECH, and EG by GC-FID and headspace GC-MS for routine batch release and regulatory submission.
Our scope covers simulated-use, exhaustive, and accelerated extractions per ISO 10993-7 Annex B and C, full extraction method validation, aeration dissipation-curve studies for cycle development, and routine batch-release residual reporting. The current ISO 10993-7:2023 limits (general-use, limited exposure ≤ 24 h: EO 4 mg/device/day, ECH 9 mg/device/day, EG 44 mg/device/day) and the proportional prolonged- and permanent-contact limits are all formally part of the testing protocol — we cite the exact edition and amendment on every report so regulators can verify against their expected version.
ETO residual analysis is performed at the Auriga Research Delhi laboratory where the GC-FID / headspace GC-MS instrumentation and ISO 10993-7 extraction suite are housed. Backed by the Arbro Group's analytical heritage — Arbro Lab since 1990, Auriga Research since 2007 — with NABL ISO/IEC 17025 accreditation, reports are accepted by CDSCO licensing authorities, FDA 510(k) reviewers, EU CE Notified Bodies, and contract sterilisers running EO cycle re-qualification.
ETO Residual Testing Parameters
Each analyte and extraction mode is mapped to its ISO 10993-7 method so sterilisation and regulatory teams can match scope to the validation dossier at a glance.
Ethylene Oxide
Residual ethylene oxide by headspace GC-FID / GC-MS — the primary toxic residue of EO sterilisation.
Ethylene Chlorohydrin
Residual ethylene chlorohydrin by solvent extraction with GC-FID.
Ethylene Glycol
Residual ethylene glycol by solvent extraction with GC-FID.
Simulated-Use Extraction
Simulated-use extraction per ISO 10993-7 Annex B / ISO 10993-12 reflecting the device’s clinical contact pattern.
Exhaustive Extraction
Exhaustive extraction to characterise worst-case patient exposure.
Accelerated Extraction
Accelerated extraction at controlled temperature for rapid screening.
Method Validation
Extraction method validation — recovery efficiency, linearity, and reproducibility.
Aeration Dissipation Curve
Multi-point aeration dissipation curve for EO cycle development and optimisation.
Routine Release
Routine batch release residual reporting for distributed lots.
Change-Driven Re-test
Re-validation testing after sterilisation cycle, material, or pack-configuration changes.
How It Works
Get a Quote
Share your device type, EO sterilisation cycle parameters, contact category (limited / prolonged / permanent), and regulatory target (CDSCO / FDA / CE). Your dedicated SPOC confirms the applicable ISO 10993-7:2023 limit, the extraction protocol (simulated-use, exhaustive, or accelerated), and the sample quantity required before you dispatch anything.
Send Your Sample
Dispatch EO-sterilised device samples in sealed primary packaging with a completed Test Request Form to the Delhi lab (or via the Bangalore collection point for south-zone clients — samples are routed to Delhi for analysis). Each sample is individually bar coded and registered in YLIMS, Auriga's in-house Laboratory Information Management System, upon receipt. Testing begins within 24 hours of sample registration.
Testing and QA Review
Your samples are extracted and analysed per ISO 10993-7:2023 by Auriga's medical device chemistry team using GC-FID and headspace GC-MS. Every EO, ECH, and EG quantification passes through a formal internal QA review against the applicable daily-dose and lifetime-dose limit before the report is generated.
Receive Your NABL Report
Your NABL-accredited ETO residual report is delivered digitally within the committed turnaround time. Reports carry Auriga's NABL accreditation under ISO/IEC 17025:2017, cite the exact ISO 10993-7 edition / amendment applied, and are accepted by CDSCO, FDA 510(k), and CE Notified Bodies. You can track sample status in real time through YLIMS.
Turnaround Time
| Service | Standard TAT | Express |
|---|---|---|
| Routine batch release (EO + ECH + EG) | 7 business days | Available |
| Standard residual analysis with simulated-use extraction | 7–10 business days | Available |
| Exhaustive extraction (worst-case exposure) | 10–14 business days | On request |
| Extraction method validation (recovery / linearity) | 15–20 business days | On request |
| Aeration dissipation curve (6 time-points) | 20–30 business days | On request |
| Gap-fill / regulatory response testing | 48–72 hours | Express only |
Who Needs ETO Residual Testing
- All EO-sterilised medical device manufacturers running routine batch release before market dispatch.
- Companies filing CDSCO Form MD-9 (manufacturing) or MD-15 (import) applications under MDR 2017.
- Manufacturers preparing FDA 510(k), De Novo, or PMA submissions where the device is EO-sterilised.
- EU CE technical-file submissions under MDR 2017/745 requiring ISO 10993-7:2023 conformity evidence.
- Contract sterilisers validating new EO cycles and re-qualifying aeration profiles after parameter changes.
- Quality teams running periodic surveillance of residuals across distributed lots and shelf-life testing.
- Class C / Class D implant manufacturers (orthopaedic, cardiovascular) requiring permanent-contact limit compliance.
- Single-use disposable manufacturers (syringes, catheters, IV sets, surgical kits) needing limited-contact release data.
- Regulatory consultants assembling sterilisation validation packages on behalf of manufacturer clients.
- Post-market complaint investigation teams responding to ETO-related sterility or biocompatibility excursions.
Why Auriga for ETO Residual Testing
NABL scope explicitly covering ISO 10993-7
ETO residual analysis is explicitly listed on our NABL scope certificate under ISO 10993-7 — not a derivative or extension. CDSCO, FDA, and CE Notified Bodies accept the report without follow-up scope verification.
Current ISO 10993-7:2023 limits applied
We test and report against the consolidated ISO 10993-7:2023 daily-dose and lifetime-dose limits — including the tightened limited-exposure thresholds and the formalised EG limit — and cite the exact edition / amendment on every report.
Dedicated GC-FID and headspace GC-MS suite
EO residuals are run on dedicated, qualified GC-FID and headspace GC-MS instruments at our Delhi laboratory — no time-share with food or pharmaceutical methods, which eliminates background-contamination risk on trace-level work.
Full extraction protocol coverage
Simulated-use, exhaustive, and accelerated extractions per ISO 10993-7 Annex B / C — selected based on your device's clinical contact pattern. We also support aeration dissipation-curve studies for EO cycle development.
CDSCO / FDA / CE acceptance trail
Reports routinely accepted in CDSCO Form MD-9 / MD-15 submissions, FDA 510(k) sterilisation sections, and CE technical files reviewed by major Notified Bodies (BSI, TÜV SÜD, DEKRA, DNV).
Arbro Group analytical heritage
Established analytical heritage through the Arbro Group (Arbro Lab since 1990, Auriga Research since 2007), with NABL ISO/IEC 17025 accreditation — the audit trail medical device manufacturers, contract sterilisers, and regulatory consultants look for in a residuals partner.